Ainos (AIMD) AI Stock Analysis

• Market Cap: $15.65M
• Dividend Yield: N/A
• Average Volume (3M): 78.00K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.08
• Revenue Growth: 70.25%
• EPS Growth: 66.22%
• Country: US
• Employees: 44
• Sector: Technology
• Sector Strength: 88
• Industry: Biotechnology
• EPS (TTM): -0.99
• Shares Outstanding: 4,771,184
• 10 Day Avg. Volume: 93,591
• 30 Day Avg. Volume: 77,998
• PEG Ratio: 0.03
• Price to Book (P/B): 1.40
• Price to Sales (P/S): 1045.31
• P/FCF Ratio: -3.72
• Enterprise Value/Market Cap: 1.37
• Enterprise Value/Revenue: 193.40
• Enterprise Value/Gross Profit: 235.03
• Enterprise Value/Ebitda: -2.11
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 38 Underperform
• Price Target: $2.50 ▼(-10.71% Downside)

Ainos' overall stock score is primarily impacted by its weak financial performance, characterized by declining revenues, persistent losses, and negative cash flows. The technical analysis further indicates a bearish trend, with the stock trading below key moving averages and technical indicators signaling oversold conditions. The valuation is also unattractive due to a negative P/E ratio and lack of dividend yield. These factors collectively suggest significant challenges for the company.

Ainos Business Overview & Revenue Model

Company Description

Ainos, Inc., a healthcare company, engages in the developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos' cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a's broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. The company was formerly known as Amarillo Biosciences, Inc. and changed its name to Ainos, Inc. in May 2021. Ainos, Inc. was incorporated in 1984 and is based in San Diego, California.

How the Company Makes Money

Ainos generates revenue primarily through the sales of its diagnostic devices and related consumables. The company’s revenue model includes direct sales to healthcare providers, hospitals, and diagnostic laboratories. Additionally, Ainos may engage in strategic partnerships with other healthcare firms or research institutions to expand its market reach and enhance product development. These collaborations can lead to co-development agreements, licensing deals, and joint marketing efforts, contributing significantly to the company's overall earnings.

Ainos Financial Statement Overview

Summary

Ainos faces considerable financial difficulties with declining revenues, persistent losses, and negative cash flows. While there are slight improvements in equity and financing, the company's financial health is weak, characterized by high leverage and operational inefficiencies. Urgent strategic adjustments are needed to stabilize and reverse the negative financial trajectory.

Income Statement

Ainos has experienced a severe decline in revenue over the years, with Total Revenue dropping to zero in the most recent year. This, coupled with negative gross and net profit margins, indicates significant operational challenges and profitability issues. There is also a lack of revenue growth, as recent results reflect a substantial decrease from previous years.

Balance Sheet

Ainos has a high debt-to-equity ratio, indicating leveraged financial structure, but the equity position has improved from negative to positive over time. However, the equity ratio remains relatively low, reflecting limited financial stability. Return on Equity is negative due to ongoing losses, suggesting inefficiencies in generating returns on shareholder investment.

Cash Flow

The company's cash flow metrics reveal persistent negative operating and free cash flows, highlighting liquidity challenges. Despite some improvements in financing activities, operating cash flow remains significantly negative compared to net income, indicating operational inefficiencies and cash flow constraints.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	110.87K	20.73K	122.11K	3.52M	594.56K	16.56K
Gross Profit	91.23K	-31.87K	-253.73K	1.41M	410.38K	5.29K
EBITDA	-10.14M	-9.44M	-8.77M	-9.14M	-1.83M	-1.43M
Net Income	-15.72M	-14.86M	-13.77M	-14.01M	-3.89M	-1.45M
Balance Sheet
Total Assets	23.92M	28.82M	31.84M	37.11M	40.82M	260.29K
Cash, Cash Equivalents and Short-Term Investments	1.22M	3.89M	1.89M	1.85M	1.75M	22.25K
Total Debt	11.00M	12.00M	5.96M	1.27M	3.62M	953.00K
Total Liabilities	12.48M	13.30M	7.39M	2.48M	30.63M	1.10M
Stockholders Equity	11.44M	15.52M	24.45M	34.63M	10.20M	-838.28K
Cash Flow
Free Cash Flow	-4.95M	-5.83M	-4.79M	-3.66M	-1.39M	-506.79K
Operating Cash Flow	-4.91M	-5.81M	-4.69M	-3.02M	-1.25M	-499.55K
Investing Cash Flow	-23.55K	-125.29K	-101.53K	-630.18K	-180.52K	-7.24K
Financing Cash Flow	-2.03M	8.03M	4.92M	3.83M	3.15M	120.00K

Ainos Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 2.80
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AIMD, the sentiment is Negative. The current price of 2.8 is below the 20-day moving average (MA) of 3.53, below the 50-day MA of 3.58, and below the 200-day MA of 3.07, indicating a bearish trend. The MACD of -0.21 indicates Positive momentum. The RSI at 31.90 is Neutral, neither overbought nor oversold. The STOCH value of 9.42 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AIMD.

Ainos Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	61 Neutral	$37.18B	12.37	-10.20%	1.83%	8.50%	-7.62%
BLRX	48 Neutral	$15.11M	-0.82	-46.42%	―	1.23%	77.75%
SNGX	39 Underperform	$13.51M	―	-169.32%	―	―	53.13%
AIMD	38 Underperform	$15.65M	-0.63	-97.80%	―	70.25%	66.22%
FBLG	38 Underperform	$16.83M	-0.68	-1292.87%	―	―	18.47%
CMMB	33 Underperform	$13.81M	-1.09	-120.76%	―	―	47.86%

Ainos Corporate Events

Ainos Amends Agreement with TCNT for Two Years

On October 15, 2025, Ainos, Inc. and TCNT amended their Product Development Agreement to extend the exclusive patent use fee arrangement to two years, starting October 16, 2025, at a rate of $50,000 per month plus sales tax. This amendment reflects ongoing collaboration and strategic adjustments between the companies, potentially impacting their market positioning and operational strategies.

The most recent analyst rating on (AIMD) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Ainos stock, see the AIMD Stock Forecast page.

Ainos Files Prospectus for Additional Share Offering

Ainos, Inc. entered into an At The Market Offering Agreement with H.C. Wainwright & Co., LLC on May 31, 2024, to sell shares of its common stock. The company initially set an aggregate offering price of $1,353,197, which was later increased to $1,840,350 on July 11, 2024. By the date of the report, Ainos had sold shares worth approximately $1,840,337. On September 5, 2025, Ainos filed a prospectus supplement to offer an additional $874,496 worth of shares.

The most recent analyst rating on (AIMD) stock is a Hold with a $3.50 price target. To see the full list of analyst forecasts on Ainos stock, see the AIMD Stock Forecast page.

Ainos, Inc. Reports Q2 2025 Financial Progress

Ainos, Inc. is a dual-platform AI and biotech company that specializes in smelltech and immune therapeutics, with its AI Nose platform digitizing scent into Smell ID for intelligent sensing applications across various industries.

Ainos Secures $2.1M Order with ASE Technology

On August 6, 2025, Ainos, Inc. announced a $2.1 million order with ASE Technology Holding Co., Ltd. for deploying its AI Nose in semiconductor manufacturing. This marks the first revenue-generating milestone for AI Nose in industrial applications, following its initial success in the senior care sector. The deployment of 1,400 AI Nose units across ASEH’s sites in Taiwan is part of Ainos’ strategy to convert strategic partnerships into active deployments, enhancing smart manufacturing through AI-powered scent intelligence. This agreement strengthens Ainos’ position in Asia’s advanced manufacturing base and reinforces its role as a pioneer in the emerging field of SmellTech.